Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986463 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1: Dose Escalation | EXPERIMENTAL | - |
| Arm 2: Dose Expansion | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986463 | DRUG | Specified dose on specified days |
Inclusion Criteria * Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1. * Participants must have at least 1 lesion accessible for biopsy in addition to the target lesion, from which a fresh pre treatment biopsy must be obtained. * Participants must have an un...
BMS-986463 is an investigational small molecule being developed for the treatment of high-grade serous ovarian carcinoma (HGSOC). It is also being studied in uterine serous carcinoma and non-small cell lung cancer. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
BMS-986463 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical trials to evaluate the safety, tolerability, and efficacy of this investigational drug.
BMS-986463 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory agencies such as the FDA. The drug is currently being evaluated in an early-stage clinical trial to assess its safety, tolerability, and preliminary efficacy.
BMS-986463 is being studied in one active clinical trial with the identifier NCT06476808. This Phase 1 study is recruiting participants with select advanced malignant tumors, including high-grade serous ovarian carcinoma, uterine serous carcinoma, and non-small cell lung cancer. The trial is enrolling 240 participants across the United States, Canada, France, Italy, and Spain.
BMS-986463 is a small molecule therapeutic. The specific molecular target of BMS-986463 has not been disclosed in available information. The drug is being evaluated in a controlled clinical trial to determine its mechanism of action and therapeutic potential in treating advanced malignant tumors.
BMS-986463 is the primary name for this investigational drug. No alternative names have been reported for this compound. It is a distinct small molecule being developed by Bristol-Myers Squibb for the treatment of certain advanced cancers, including high-grade serous ovarian carcinoma.